262 related articles for article (PubMed ID: 12605964)
1. Eye retention after proton beam radiotherapy for uveal melanoma.
Egger E; Zografos L; Schalenbourg A; Beati D; Böhringer T; Chamot L; Goitein G
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):867-80. PubMed ID: 12605964
[TBL] [Abstract][Full Text] [Related]
2. Proton beam radiotherapy of uveal melanoma: Italian patients treated in Nice, France.
Mosci C; Mosci S; Barla A; Squarcia S; Chauvel P; Iborra N
Eur J Ophthalmol; 2009; 19(4):654-60. PubMed ID: 19551683
[TBL] [Abstract][Full Text] [Related]
3. Proton therapy for uveal melanoma in 43 juvenile patients: long-term results.
Petrovic A; Bergin C; Schalenbourg A; Goitein G; Zografos L
Ophthalmology; 2014 Apr; 121(4):898-904. PubMed ID: 24405742
[TBL] [Abstract][Full Text] [Related]
4. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy.
Conway RM; Poothullil AM; Daftari IK; Weinberg V; Chung JE; O'Brien JM
Arch Ophthalmol; 2006 Jun; 124(6):838-43. PubMed ID: 16769837
[TBL] [Abstract][Full Text] [Related]
5. Linear accelerator-based stereotactic fractionated photon radiotherapy as an eye-conserving treatment for uveal melanoma.
Akbaba S; Foerster R; Nicolay NH; Arians N; Bostel T; Debus J; Hauswald H
Radiat Oncol; 2018 Aug; 13(1):140. PubMed ID: 30071857
[TBL] [Abstract][Full Text] [Related]
6. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients.
Shields CL; Naseripour M; Cater J; Shields JA; Demirci H; Youseff A; Freire J
Ophthalmology; 2002 Oct; 109(10):1838-49. PubMed ID: 12359604
[TBL] [Abstract][Full Text] [Related]
7. The risk of enucleation after proton beam irradiation of uveal melanoma.
Egan KM; Gragoudas ES; Seddon JM; Glynn RJ; Munzenreider JE; Goitein M; Verhey L; Urie M; Koehler A
Ophthalmology; 1989 Sep; 96(9):1377-82; discussion 1382-3. PubMed ID: 2550868
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
9. Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years' experience.
Caujolle JP; Mammar H; Chamorey E; Pinon F; Herault J; Gastaud P
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):98-103. PubMed ID: 19910136
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up after uveal melanoma charged particle therapy.
Char DH; Kroll SM; Castro J
Trans Am Ophthalmol Soc; 1997; 95():171-87; discussion 187-91. PubMed ID: 9440169
[TBL] [Abstract][Full Text] [Related]
11. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients.
Shields CL; Shields JA; Cater J; Gündüz K; Miyamoto C; Micaily B; Brady LW
Arch Ophthalmol; 2000 Sep; 118(9):1219-28. PubMed ID: 10980767
[TBL] [Abstract][Full Text] [Related]
12. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO).
Dendale R; Lumbroso-Le Rouic L; Noel G; Feuvret L; Levy C; Delacroix S; Meyer A; Nauraye C; Mazal A; Mammar H; Garcia P; D'Hermies F; Frau E; Plancher C; Asselain B; Schlienger P; Mazeron JJ; Desjardins L
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):780-7. PubMed ID: 16647221
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.
Böker A; Pilger D; Cordini D; Seibel I; Riechardt AI; Joussen AM; Bechrakis NE
Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1767-1775. PubMed ID: 29907945
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: a detailed analysis of tumor and dose-volume parameters.
Mishra KK; Daftari IK; Weinberg V; Cole T; Quivey JM; Castro JR; Phillips TL; Char DH
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):330-6. PubMed ID: 23886415
[TBL] [Abstract][Full Text] [Related]
15. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma.
Egger E; Schalenbourg A; Zografos L; Bercher L; Boehringer T; Chamot L; Goitein G
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):138-47. PubMed ID: 11516863
[TBL] [Abstract][Full Text] [Related]
16. Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma.
Seibel I; Cordini D; Hager A; Tillner J; Riechardt AI; Heufelder J; Davids AM; Rehak M; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1787-92. PubMed ID: 27376824
[TBL] [Abstract][Full Text] [Related]
17. [Results of treating uveal melanoma with proton beam radiation: 10-year follow-up].
Hamrouni Z; Levy C; Lumbroso L; D'Hermies F; Frau E; Mazal A; Delacroix S; Nauraye C; Dendale R; Schlienger P; Desjardins L
J Fr Ophtalmol; 2005 Oct; 28(8):833-9. PubMed ID: 16249762
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.
Mahdjoubi A; Najean M; Lemaitre S; Dureau S; Dendale R; Levy C; Rouic LL; Desjardins L; Cassoux N
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):411-420. PubMed ID: 29116399
[TBL] [Abstract][Full Text] [Related]
19. Proton beam therapy for the treatment of uveal melanoma in Scotland.
Macdonald EC; Cauchi P; Kemp EG
Br J Ophthalmol; 2011 Dec; 95(12):1691-5. PubMed ID: 21216794
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Radiosurgery and Fractionated Stereotactic Radiation Therapy for the Treatment of Uveal Melanoma.
Yazici G; Kiratli H; Ozyigit G; Sari SY; Cengiz M; Tarlan B; Mocan BO; Zorlu F
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):152-158. PubMed ID: 28586956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
